Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor D Bandeira

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Harvard Review of Psychiatry|March 10, 2022
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic ReviewIgor D Bandeira, Daniel H Lins-Silva, Vitor Breseghello Cavenaghi, et al.
Journal of Clinical Psychopharmacology|June 21, 2022
Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic DepressionBreno Souza-Marques, Manuela Telles, Gustavo C Leal, et al.
Iscience|March 26, 2026
Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocolAndrew D Geoly, John P Coetzee, Derrick Matthew Buchanan, et al.
Journal of Psychiatric Research|June 29, 2023
Arketamine for bipolar depression: Open-label, dose-escalation, pilot studyIgor D Bandeira, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Psychiatry Research|March 15, 2023
Psychopathological symptoms in parents and siblings of people on the autism spectrum: A systematic review and meta-analysisAna Cecília Bispo-Torres, Rita Lucena, Ivo César Tavares-Rodrigues, et al.
Human Psychopharmacology|February 18, 2022
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depressionAna Paula Jesus-Nunes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Journal of Psychiatric Research|May 15, 2021
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trialRodrigo P Mello, Mariana V F Echegaray, Ana Paula Jesus-Nunes, et al.
Trends in Psychiatry and Psychotherapy|December 14, 2021
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trialAna Teresa Caliman-Fontes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Trends in Psychiatry and Psychotherapy|September 17, 2023
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trialMariana V F Echegaray, Rodrigo P Mello, Guilherme M Magnavita, et al.
European Archives of Psychiatry and Clinical Neuroscience|February 21, 2020
Intravenous arketamine for treatment-resistant depression: open-label pilot studyGustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Harvard Review of Psychiatry|March 10, 2022
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic ReviewIgor D Bandeira, Daniel H Lins-Silva, Vitor Breseghello Cavenaghi, et al.
Journal of Clinical Psychopharmacology|June 21, 2022
Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic DepressionBreno Souza-Marques, Manuela Telles, Gustavo C Leal, et al.
Iscience|March 26, 2026
Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocolAndrew D Geoly, John P Coetzee, Derrick Matthew Buchanan, et al.
Journal of Psychiatric Research|June 29, 2023
Arketamine for bipolar depression: Open-label, dose-escalation, pilot studyIgor D Bandeira, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Psychiatry Research|March 15, 2023
Psychopathological symptoms in parents and siblings of people on the autism spectrum: A systematic review and meta-analysisAna Cecília Bispo-Torres, Rita Lucena, Ivo César Tavares-Rodrigues, et al.
Human Psychopharmacology|February 18, 2022
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depressionAna Paula Jesus-Nunes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Journal of Psychiatric Research|May 15, 2021
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trialRodrigo P Mello, Mariana V F Echegaray, Ana Paula Jesus-Nunes, et al.
Trends in Psychiatry and Psychotherapy|December 14, 2021
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trialAna Teresa Caliman-Fontes, Gustavo C Leal, Fernanda S Correia-Melo, et al.
Trends in Psychiatry and Psychotherapy|September 17, 2023
Does the intensity of dissociation predict antidepressant effects 24 hours after infusion of racemic ketamine and esketamine in treatment-resistant depression? A secondary analysis from a randomized controlled trialMariana V F Echegaray, Rodrigo P Mello, Guilherme M Magnavita, et al.
European Archives of Psychiatry and Clinical Neuroscience|February 21, 2020
Intravenous arketamine for treatment-resistant depression: open-label pilot studyGustavo C Leal, Igor D Bandeira, Fernanda S Correia-Melo, et al.
Pageof 4